Chevy Chase Trust’s Alaunos Therapeutics TCRT Stock Holding History

Chevy Chase Trust’s Portfolio TCRT Stock Details TCRT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-112	Closed	-$60K	–	684
2021 Q1	$60K	Sell	112 -78	-41%	-$48.6K	﹤0.01%	675
2020 Q4	$72K	Buy	+190	New	+$75.5K	﹤0.01%	650
2020 Q1	–	Sell	-33	Closed	-$24K	–	984
2019 Q4	$24K	Buy	+33	New	+$22.7K	﹤0.01%	972
2019 Q2	–	Sell	-67	Closed	-$44K	–	658
2019 Q1	$44K	Hold	67	–	–	﹤0.01%	653
2018 Q4	$19K	Hold	67	–	–	﹤0.01%	707
2018 Q3	$32K	Sell	67 -46	-41%	-$19.7K	﹤0.01%	659
2018 Q2	$51K	Hold	113	–	–	﹤0.01%	667
2018 Q1	$67K	Hold	113	–	–	﹤0.01%	654
2017 Q4	$70K	Hold	113	–	–	﹤0.01%	665
2017 Q3	$104K	Buy	+113	New	+$100K	﹤0.01%	654
2015 Q2	–	Sell	-79	Closed	-$128K	–	685
2015 Q1	$128K	Buy	+79	New	+$117K	﹤0.01%	659

Other funds holding TCRT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return

DCM

Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

MVP

Miller Value Partners Sarasota, Florida $383M AUM 38.57% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Chevy Chase Trust's TCRT Position: Q2 2021 in Review

Chevy Chase Trust sold out of Alaunos Therapeutics (TCRT) in Q2 2021, closing a stake of 112 shares — an estimated $60K sold.

Chevy Chase Trust first reported a position in TCRT in Q1 2015 and held it in 11 quarters. The position peaked at $128K in Q1 2015. 155 funds tracked by Wall St. Rank hold TCRT as of Q2 2021.

Chevy Chase Trust reported no remaining Alaunos Therapeutics position as of Q2 2021 after selling out during the quarter.
Chevy Chase Trust sold 112 Alaunos Therapeutics shares in Q2 2021, an estimated $60K.
Chevy Chase Trust first reported a position in Alaunos Therapeutics in Q1 2015 and held it in 11 quarters.
Chevy Chase Trust's Alaunos Therapeutics position peaked at $128K in Q1 2015.
155 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q2 2021.

Based on Chevy Chase Trust's 13F filing for Q2 2021, filed 20 Jul 2021.